Spots Global Cancer Trial Database for Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001
Official Title: A Phase 1, First-in-Human, Open-Label, Dose Escalation and Dose Expansion Study of FTL001 in Patients With Advanced or Metastatic Solid Tumors
Study ID: NCT06410092
Conditions
Interventions
Study Description
Brief Summary: This is an open, multi-center, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics/pharmacokinetics and initial efficacy of FTL001 in patients with advanced and metastatic solid tumors.
Detailed Description: The study is divided into two phases, Part 1 (FTL001 dose escalation) and Part 2 (FTL001 dose expansion), and is intended to include approximately 26-44 participants.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
West China Hospital, Chengdu, Sichuan, China
Contact Details
Name: Yuankai Shi, MD
Affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR
Name: Shoubin Wen, MD
Affiliation: Sound Biopharmaceuticals Ltd.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
